Descriptor English: | Levodopa | ||||||
Descriptor Spanish: |
Levodopa
| ||||||
Descriptor Portuguese: | Levodopa | ||||||
Descriptor French: | Lévodopa | ||||||
Entry term(s): |
3 Hydroxy L tyrosine 3-Hydroxy-L-tyrosine Dopaflex Dopar L 3,4 Dihydroxyphenylalanine L Dopa L-3,4-Dihydroxyphenylalanine L-Dopa Larodopa Levopa |
||||||
Tree number(s): |
D02.092.311.200.480 D02.455.426.559.389.657.166.175.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D007980 | ||||||
Scope note: | The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis DF deficiency EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Antiparkinson Agents Dopamine Agents |
||||||
Registry Number: | 46627O600J | ||||||
Previous Indexing: |
Dopa (1966-1974) |
||||||
Public MeSH Note: | 75; was see DOPA 1972-74 |
||||||
Online Note: | search DOPA 1972-74 |
||||||
History Note: | 75; was see DOPA 1972-74 |
||||||
Related: |
Dopamine
MeSH | ||||||
DeCS ID: | 24230 | ||||||
Unique ID: | D007980 | ||||||
NLM Classification: | WK 725 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1975/01/01 | ||||||
Date of Entry: | 1999/01/01 | ||||||
Revision Date: | 2018/06/30 |
-
-
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Levodopa
- Preferred
Levopa
- Narrower
Larodopa
- Narrower
Dopaflex
- Narrower
Dopar
- Narrower
Concept UI |
M0012434 |
Scope note | The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. |
Preferred term | Levodopa |
Entry term(s) |
3 Hydroxy L tyrosine 3-Hydroxy-L-tyrosine L 3,4 Dihydroxyphenylalanine L Dopa L-3,4-Dihydroxyphenylalanine L-Dopa |
Concept UI |
M0351195 |
Preferred term | Levopa |
Concept UI |
M0012435 |
Preferred term | Larodopa |
Concept UI |
M0463388 |
Preferred term | Dopaflex |
Concept UI |
M0463389 |
Preferred term | Dopar |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey